Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Moderna, Inc. (MRNA) Price & Performance

MasterCard IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Moderna, Inc. — how do they compare? MasterCard Inc trades at $561.13 (market cap $491.83B), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: MasterCard Inc is far larger — about 20.3× Moderna, Inc.'s market cap, and MasterCard Inc pays a 0.62% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

MAMRNA
Market Cap
$491.83B$24.18B
Volume
4,635,698
Sector
Consumer CyclicalHealth
52-Week High
$598.96$81.80
52-Week Low
$471.55$22.36
Enterprise Value
$504.86B$20.33B
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $559.88, down 0.58% today, with strong technical support at $559 and resistance at $566. The stock shows robust fundamentals, with Q2 2026 EPS beating expectations at $5.04 versus $4.77, and revenue growth accelerating to $32.79B in 2025. Analysts maintain a bullish consensus, with 79% buy ratings and a $660.85 price target, while institutional buying activity remains positive, as noted in recent SEC filings.

Outlook is positive due to consistent earnings beats, high profitability margins, and strategic initiatives in digital payments and AI. Risks include competition from emerging payment technologies like stablecoins, as highlighted by The Motley Fool on April 10, 2026, and elevated valuation multiples such as a P/E of 30.88, which may limit near-term upside if growth slows.

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA